Zenas BioPharma (NASDAQ:ZBIO) Trading Down 7% – Time to Sell?

Zenas BioPharma, Inc. (NASDAQ:ZBIO)’s stock price was down 7% during mid-day trading on Wednesday . The company traded as low as $21.44 and last traded at $20.91. Approximately 74,846 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 995,456 shares. The stock had previously closed at $22.48.

Analyst Ratings Changes

A number of research analysts have commented on ZBIO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Wall Street Zen lowered shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 21st. Morgan Stanley increased their price target on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday, March 17th. Finally, Citigroup lowered their price objective on Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Stock Performance

The stock’s 50-day moving average price is $23.28 and its 200-day moving average price is $27.38. The company has a current ratio of 5.61, a quick ratio of 5.61 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $1.19 billion, a P/E ratio of -2.65 and a beta of -0.54.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Buying and Selling

In related news, Director Hongbo Lu purchased 25,985 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were acquired at an average price of $22.50 per share, with a total value of $584,662.50. Following the acquisition, the director owned 347,968 shares in the company, valued at approximately $7,829,280. This trade represents a 8.07% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Patricia L. Allen acquired 15,700 shares of Zenas BioPharma stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average price of $24.85 per share, with a total value of $390,145.00. Following the transaction, the director directly owned 15,700 shares in the company, valued at approximately $390,145. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 306,613 shares of company stock valued at $5,998,383 over the last three months. 22.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds have recently added to or reduced their stakes in ZBIO. Polar Capital Holdings Plc bought a new position in shares of Zenas BioPharma during the fourth quarter worth about $38,402,000. Federated Hermes Inc. lifted its position in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares during the last quarter. EcoR1 Capital LLC acquired a new position in Zenas BioPharma during the 4th quarter valued at about $28,667,000. NEA Management Company LLC boosted its stake in Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares during the period. Finally, NEXTBio Capital Management LP bought a new position in Zenas BioPharma in the 4th quarter worth about $11,691,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.